Krystal Biotech/KRYS

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Krystal Biotech

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Ticker

KRYS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Pittsburgh, United States

Employees

229

Krystal Biotech Metrics

BasicAdvanced
$5.1B
Market cap
89.33
P/E ratio
$1.99
EPS
0.90
Beta
-
Dividend rate
$5.1B
0.9
12.655
12.287
0.809
0.988
-4.97%
8.87%
89.33
51.46
6.24
6.24
-90.7
-137.68%
-2.69%

What the Analysts think about Krystal Biotech

Analyst Ratings

Majority rating from 10 analysts.
Buy

Krystal Biotech Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
1.99% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$45M
7.36%
Net income
$900K
-89.53%
Profit margin
1.99%
-90.25%

Krystal Biotech Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 79.61%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.25
$2.79
$0.30
$0.03
-
Expected
-$0.74
-$0.29
-$0.43
$0.15
$0.62
Surprise
69.68%
-1,075.52%
-170.59%
-79.61%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Krystal Biotech stock?

Krystal Biotech (KRYS) has a market cap of $5.1B as of July 04, 2024.

What is the P/E ratio for Krystal Biotech stock?

The price to earnings (P/E) ratio for Krystal Biotech (KRYS) stock is 89.33 as of July 04, 2024.

Does Krystal Biotech stock pay dividends?

No, Krystal Biotech (KRYS) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Krystal Biotech dividend payment date?

Krystal Biotech (KRYS) stock does not pay dividends to its shareholders.

What is the beta indicator for Krystal Biotech?

Krystal Biotech (KRYS) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Krystal Biotech stock

Buy or sell Krystal Biotech stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing